Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment

Edited by
October 2020
128 pages
  • ISBN978-3-03936-658-3 (Hardback)
  • ISBN978-3-03936-659-0 (PDF)

This book is a reprint of the Special Issue Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment that was published in

Biology & Life Sciences
Medicine & Pharmacology
Public Health & Healthcare
Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB) and it represents a persistent public health threat for a number of complex biological and sociological reasons. According to the most recent Global Tuberculosis Report (2019) edited by the World Health Organization (WHO), TB is considered the ninth cause of death worldwide and the leading cause of mortality by a single infectious agent, with the highest rate of infections and death toll rate mostly concentrated in developing and low-income countries. We present here the editorial section to the Special Issue entitled “Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment” that includes 7 research articles and a review. The scientific contributions included in the Special Issue mainly focus on the characterization of MTB strains emerging in TB endemic countries as well as on multiple mechanisms adopted by the bacteria to resist and to adapt to antitubercular therapies.
  • Hardback
License and Copyright
© 2020 by the authors; CC BY-NC-ND license
Mycobacterium tuberculosis; line probe assay; second-line drugs; drug resistance; XDR-TB; MDR-TB; omics analysis; TB treatment; system analysis; Beijing B0/W148; Mycobacterium smegmatis; imidazo[1,2-b][1,2,4,5]tetrazine; MmpS5-MmpL5; efflux; drug discovery; drug resistance; tuberculosis; immune activation; HLA-DR; CD38; treatment response; Mycobacterium; macrophage; apoptosis; effector; cytokine; microRNA; Beijing genotype; Central Asia Outbreak; murine infection model; Virulence; pre-XDR-TB; Mycobacterium avium; tuberculosis; unique metabolic pathways; subtractive genomics; drug target; uncharacterized proteins; BM-MSCs; Mtb; bone-homing; stem cell niche; latent tuberculosis; relapse; liposomes; M. tuberculosis; tuberculosis; host-pathogen interactions; immune response; antitubercular drug discovery; antitubercular treatments; tuberculosis; IL-18; IL-18BP; IL-18R; gene expression